Clinical trial
Topotecan in Combination With Pemetrexed in Patients With Advanced Malignancies
NCT00315861 · SCRI Development Innovations, LLC, Other · Completed
Key facts
| NCT number | NCT00315861 |
|---|---|
| Title | Topotecan in Combination With Pemetrexed in Patients With Advanced Malignancies |
| Official title | A Phase I Study of Topotecan in Combination With Pemetrexed in Patients With Advanced Malignancies |
| Lead sponsor | SCRI Development Innovations, LLC, Other |
| Collaborators | GlaxoSmithKline Industry Eli Lilly and Company |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Ovarian Cancer, Endometrial Cancer, Cervical Cancer, Lung Cancer |
| Intervention type | Drug |
| Interventions | pemetrexed, topotecan |
| Enrollment | 15 |
| Start date | Mar 1, 2006 |
| Primary completion | May 1, 2008 |
| Completion | Jan 1, 2009 |
| First posted | Apr 19, 2006 |
| Last update posted | Jan 23, 2009 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: